Abstract
Background: Early biomarkers predictive for long-term morbidity and mortality are needed following perinatal asphyxia. S-100B specific for glial cells of CNS is elevated in the serum after brain damage in adults and in neonates.
Aim: To assess the relationship of serum S-100B levels and neurodevelopmental outcome in asphyxiated neonates.
Methods: 30 newborns with perinatal asphyxia were studied. Serum S-100B was measured using chemiluminescence method at 6 hours of age. Neurodevelopmental assessment (Bayley II test) was performed between 18-22 months. Infants were classified into two groups: i) healthy infants and infants with mild neurological impairment (MDI or PDI> 70; group M) [n = 19] ii) infants with severe developmental delay or death (MDI or PDI< 70; group S) [n = 11]. Mann-Whitney U-test was used for statistics.
Results: The anthropometric characteristics of the two groups were comparable. S-100B values were significantly lower in group E compared to group M (µg/l) [median; min-max]: 2,15; 0,52-18,1; and 32,81; 0,88-151, (p< 0,0005) respectively. 20 µg/l S-100B level was chosen as cut-off value (sensitivity: 0,58; specificity: 1; PPV: 1; NPV: 0,78 for the adverse outcome).
Conclusions: Serum S-100B was significantly higher in the adverse outcome group compared to the optimal outcome group. S-100B appears to be a good biomarker for early prognosis, it correlates with the severity of neurological impairment but further studies are necessary.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nagy, D., Borbély, E., Lakatos, P. et al. Serum S-100B Protein as an Outcome Biomarker in Neonates After Perinatal Asphyxia. Pediatr Res 70 (Suppl 5), 195 (2011). https://doi.org/10.1038/pr.2011.420
Issue Date:
DOI: https://doi.org/10.1038/pr.2011.420